Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
2315.HK Stock Price Chart
Explore Biocytogen Pharmaceuticals (Beijing) Co., Ltd. interactive price chart. Choose custom timeframes to analyze 2315.HK price movements and trends.
2315.HK Company Profile
Discover essential business fundamentals and corporate details for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Sept 2022
Employees
1.12K
Website
https://biocytogen.com.cnCEO
Yuelei Shen
Description
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-regional clinical trials and two products are in Phase I clinical trials. It focuses on developing drugs in the areas of oncology, autoimmune, inflammatory, metabolic, and other diseases. The company was founded in 2009 and is headquartered in Beijing, China. Beijing Biocytogen Co., Ltd. develops and prepares gene engineered animals to large-scale supply of animal models. It offers preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models. The company's products include B-NDG mice, cre mouse models, cre rat models, B-p53 KO mice, B-ApoE KO mice, B-hIL6 mice, B-IL17-EGFP KI mice, B-TGFb1 cKO mice, genome- edited hESC, luciferase reported stable tumor cell lines, B-Pink1 KO rats, B-IL2rg KO rats, B-Cas9D10A cKI rats, B-ApoA4 KO rats, B-LDLR KO rats, B-Prkdc KO rats, B-Rag2 KO rats, B-tdTomato cKI rats, B-ApoE KO rats, B-hTnf mice, and B-hFcgrt (FcRn) mice. Beijing Biocytogen Co., Ltd. also develops antibody research and development platform and provides pharmacology services in the areas of tumor immunity, tumor and autoimmunity, and in vivo and in vitro pharmacology and pharmacology service platform. It also sells its products online. The company was founded in 2008 and is based in Beijing, China with additional locations in Beijing, Haimen, Jiangsu, Shanghai, China; Heidelberg, Germany; and Boston, the United States.
2315.HK Financial Timeline
Browse a chronological timeline of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 25 Mar 2025
Earnings released on 29 Aug 2024
EPS came in at -$0.07 surpassing the estimated -$0.13 by +46.61%, while revenue for the quarter reached $222.06M , missing expectations by -49.62%.
Earnings released on 30 Jun 2024
EPS came in at -$0.07 , while revenue for the quarter reached $220.42M .
Earnings released on 27 Mar 2024
EPS came in at -$0.26 surpassing the estimated -$0.48 by +46.27%, while revenue for the quarter reached $209.19M , missing expectations by -48.29%.
Earnings released on 31 Dec 2023
EPS came in at -$0.27 , while revenue for the quarter reached $215.87M .
Earnings released on 28 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$0.44 by +38.63%, while revenue for the quarter reached $186.54M , missing expectations by -45.00%.
Earnings released on 30 Jun 2023
EPS came in at -$0.26 , while revenue for the quarter reached $176.72M .
Earnings released on 27 Mar 2023
EPS came in at -$0.47 surpassing the estimated -$0.55 by +15.69%, while revenue for the quarter reached $167.39M , missing expectations by -57.47%.
Earnings released on 31 Dec 2022
EPS came in at -$0.48 , while revenue for the quarter reached $173.54M .
Earnings released on 26 Sept 2022
EPS came in at -$0.43 , while revenue for the quarter reached $134.12M .
Earnings released on 19 Aug 2022
EPS came in at -$0.45 , while revenue for the quarter reached $141.19M .
Earnings released on 31 Dec 2021
EPS came in at -$0.50 , while revenue for the quarter reached $136.82M .
Earnings released on 30 Sept 2021
EPS came in at -$0.49 , while revenue for the quarter reached $134.79M .
Earnings released on 30 Jun 2021
EPS came in at -$0.42 , while revenue for the quarter reached $78.67M .
Earnings released on 31 Mar 2021
EPS came in at -$0.41 , while revenue for the quarter reached $77.60M .
2315.HK Stock Performance
Access detailed 2315.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.